A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Study type

Interventional

Primary purpose

Treatment

Allocation

Randomized

Intervention model

Parallel

Masking

None

Arms

4

Interventions

• Ivonescimab Dose 1 Drug
• enfortumab vedotin (EV) Drug
• Pembrolizumab Drug
• Ivonescimab Dose 2 Drug
• Ivonescimab RP3D Drug

• Metastatic Urothelial Carcinoma
• Metastatic Urothelial Carcinoma (UC)

Primary outcome

Phase 2 Primary Outcome Measure (Through 90 days after the last study treatment); Phase 2 Primary Outcome Measure (From first dose until approximately 30 days after the last study treatment, assessed up to 3 years); Phase 2 Primary Outcome measure (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years); Phase 2 Primary Outcome Measure (From first dose until end of treatment, assessed up to 3 years); Phase 3 Primary Outcome Measure (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.); Phase 3 Primary Outcome Measure (From date of randomization until the end of study, assessed up to 4 years)

• Ivonescimab
• Ivonescimab RP3D

• NCT07815665 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read 25 Oct 2026

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.